The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer
A Randomized Controlled Trial to Evaluate the Efficacy and Safety of Docetaxel Combined With Platinum-based Drugs Compared With Docetaxel Alone for Metastatic Hormone-sensitive Prostate Cancer Patients Carrying DNA Repair Mutation
Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
A PHASE2 clinical study on Chemotherapeutic Toxicity and Chemotherapy Effect, this trial is ongoing. The trial is conducted by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School and has accumulated 5 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Feb 2026 — Present [monthly]
Unknown PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — Feb 2026 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Nov 2022 — Jul 2024 [monthly]
Recruiting PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE2
First recorded
Jul 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
For direct contact, visit the study record on ClinicalTrials.gov .